Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$14.6 million.

  • Barinthus Biotherapeutics' Profit After Tax fell 7924.71% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.9 million, marking a year-over-year decrease of 3120.83%. This contributed to the annual value of -$61.2 million for FY2024, which is 1669.78% up from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Profit After Tax stood at -$14.6 million, which was down 7924.71% from -$21.1 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Profit After Tax high stood at $15.7 million for Q2 2022, and its period low was -$23.8 million during Q2 2023.
  • Its 5-year average for Profit After Tax is -$12.4 million, with a median of -$15.5 million in 2024.
  • In the last 5 years, Barinthus Biotherapeutics' Profit After Tax tumbled by 238500.0% in 2021 and then soared by 28035.01% in 2022.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Profit After Tax stood at -$15.2 million in 2021, then tumbled by 39.67% to -$21.2 million in 2022, then grew by 18.4% to -$17.3 million in 2023, then fell by 19.09% to -$20.6 million in 2024, then rose by 29.24% to -$14.6 million in 2025.
  • Its Profit After Tax was -$14.6 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$19.7 million in Q1 2025.